CAS: 664-95-9; Cyclamide
化学文摘社编号664-95-9,属于氨化物类别,其特征是存在一种矿和一种碳酸功能组,这种物质组具有极分子特性.在室温下,甘蓝酰胺一般是一种白色晶体,由于它能够形成氢结体,在水中可溶解.该化合物经常被研究其潜在在制药和生物化学中的应用,特别是其作为各种生物活性分子合成中一个构件的作用.其结构包括一种甘蓝的细胞,这是一种氨酸,与生物系统相关.甘蓝可展示各种生物活动,其与其他分子的相互作用可能受到诸如pH和温度等因素的影响.与许多化学物质一样,应观测安全性和处理预防措施,因为它可能具有具体的毒性或反应性特征,需要实验室环境中的注意.
- ⚠️《化妆品禁用原料目录》
- 英文名称Cyclamide
- 中文名称环酰胺
- IUPAC名称1-Cyclohexyl-3-p-tolylsulfonylurea
- 其它别名Urea,1-cyclohexyl-3-(p-tolylsulfonyl)- (8CI); 1-(p-Tolylsulfonyl)-3-cyclohexylurea; 1-Cyclohexyl-3-p-tolylsulfonylurea; Agliral; Cicloral; Cychloral; Cyclamid; Cyclamide; Cyclamide (Russian); Diaboral; Gliciclamide; Glycyclamid; Glycyclamide; N-(4-Tolylsulfonyl)-N'-cyclohexylurea; N-Cyclohexyl-N'-(p-tolylsulfonyl)urea; Tolcyclamide; Tolhexamide; Tsiklamid
- CAS编号664-95-9
- MFCD编号:MFCD00242887
- EINECS号:211-557-6
- FDA UNII编号:C40N4EJY68
- 分子式:C2H6N2O分子量:74.08184
- 产品CID: 1646402
- 产品分类有机原料→分子砌块→芳环类化合物→苯类化合物
物理性质
MSDS等安全信息
上下游产品
CAS号70-55-3 对甲苯磺酰胺 | CAS号3173-53-3 环己基异氰酸酯 | CAS号4083-64-1 对甲基苯磺酰异氰酸酯 | CAS号108-91-8 环己胺 | CAS号5577-13-9 N-(4-甲基苯基)磺酰氨基甲酸乙酯 | CAS号98-59-9 对甲苯磺酰氯(PTSC) | CAS号766-93-8 N-环己基甲酰胺 | CAS号109840-62-2 (N-cyclohexyl-f... | CAS号7647-01-0 盐酸合成工艺路线路线简述
📜对甲苯磺酰胺,环己基异氰酸酯置于copper(L) Chloride体系中,用 N,N-二甲基甲酰胺 作为反应溶剂,化学反应 24.0H,以98%的收率获得产物格列环脲
参考文献:An Improved Method For The Synthesis Of Sulfonylureas
标题:An Improved Method For The Synthesis Of Sulfonylureas
摘要:在温和条件下,使用氯化铜(I)的存在下,将异氰酸酯与磺酰胺在二甲基甲酰胺中反应,可以高效合成磺酰脲.
DOI:10.1055/s-1990-26837
海关参考信息
- 2902300000-甲苯
2912110000-甲醛
2921199090-其他无环单胺 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.
专利号:EP-1551403-B1
优先权日:2002-10-10
标 题 :5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
发明人：SEMPLE GRAEME; AVERBUJ CLAUDIA; SKINNER PHILIP; GHARBAOUI TAWFIK; SHIN YOUNG-JUN
权利人:ARENA PHARM INC
摘要:The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R2 is H, halogen, C1-12 alkyl or C1-12 haloalkyl; and R3 is C3-6 cycloalkyl, C1-12 alkyl, C1-12 haloalkyl, C3-6 cycloalkyl-C1-4-alkylene, aryl-C1-4-alkylene or heteroaryl-C1-4-alkylene, wherein said aryl-C1-4-alkylene and heteroaryl-C1-4-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of alpha-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.
专利号:US-2006122240-A1
优先权日:2002-11-05
标题 :Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof
发明人：SEMPLE GRAEME; SKINNER PHILIP J; CHERRIER MARTIN C; WEBB PETER; TAMURA SUSAN Y
权利人:ARENA PHARM INC
摘要:The present invention relates to certain benzotriazole carboxylic acid or ester derivatives of Formula (I), pharmaceutically acceptable salts and solvates thereof, which exhibit useful pharmaceutical properties, for example, as agonists for the GPCR referred to as hRUP38. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
专利号:US-2007032537-A1
优先权日:2003-06-13
标题:5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases
发明人：SEMPLE GRAEME; GHARBAOUI TAWFIK; SHIN YOUNG-JUN; DECAIRE MARC; AVERBUJ CLAUDIA L; SKINNER PHILIP J
权利人:ARENA PHARM INC
摘要:The present invention relates to certain pyrazole carboxylic acid and ester derivatives, and pharmaceutically acceptable salts thereof, which exhibit useful pharmaceutical properties, for example as agonists for the RUP25 receptor. (I) Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like the substituents are defined in claim 1.
专利号:US-2004082548-A1
优先权日:1999-04-01
标 题 :Intermediates for the synthesis of ether compounds
专利号:KR-20190108383-A
优先权日:2018-03-14
标题 :Novel synthesis of cyclen using oxamide and lithium aluminium hydride
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Trezzini C, Splendori F. [Clinical observations on the combination of glycyclamide and dimethylbiguanide in the treatment of diabetes in the aged]. Clin Ter. 1969 Apr 15;49(1):23-34. Italian. Italian. doi: 10.1002/cbic.201000193.
4: GENES SG, MAKAREVICH-GAL'PERIN LM, USHENKO SN. [Effect of butamide, cyclamide, chlorcyclamide and chloropropamide on the glycogen content in various tissues]. Vopr Med Khim. 1960 Sep-Oct;6:469-74. Russian. Russian. Russian. Russian. Spanish. Spanish.
合成参考文献
摘要:Farmaco, Edizione Scientifica., 12(268), 1957
摘要:Research Progress in Organic-Biological and Medicinal Chemistry., 2(280), 1970
参考文献:10.1248/cpb.56.541
摘要:Xi PX, Xu ZH, Liu XH, Chen FJ, Huang L, Zeng ZZ. Synthesis, characterization, antioxidant activity, and DNA-binding studies of 1-cyclohexyl-3-tosylurea and its Nd(III), Eu(III) complexes. Chem Pharm Bull (Tokyo). 2008 Apr;56(4):541–6. doi: 10.1248/cpb.56.541.
参考文献:10.1186/1471-2164-9-274
摘要:Frangeul L, Quillardet P, Castets AM, Humbert JF, Matthijs HC, Cortez D, Tolonen A, Zhang CC, Gribaldo S, Kehr JC, Zilliges Y, Ziemert N, Becker S, Talla E, Latifi A, Billault A, Lepelletier A, Dittmann E, Bouchier C, de Marsac NT. Highly plastic genome of Microcystis aeruginosa PCC 7806, a ubiquitous toxic freshwater cyanobacterium. BMC Genomics. 2008 Jun 05;9():274.
📝 需求与反馈
尽可能描述清楚需求与问题信息
